CAS 934526-89-3

Pilaralisib

Description:

Pilaralisib, with the CAS number 934526-89-3, is a selective inhibitor of the phosphoinositide 3-kinase (PI3K) pathway, specifically targeting the delta isoform (PI3Kδ). This compound is primarily investigated for its potential therapeutic applications in oncology and autoimmune diseases, as the PI3K pathway plays a crucial role in cell growth, proliferation, and survival. Pilaralisib exhibits a favorable pharmacokinetic profile, allowing for oral administration, and has been studied in various clinical trials to assess its efficacy and safety in treating conditions such as lymphoma and other hematological malignancies. Its mechanism of action involves the inhibition of PI3Kδ, which is predominantly expressed in leukocytes, thereby modulating immune responses and tumor growth. As with many targeted therapies, the development of Pilaralisib has been accompanied by research into biomarkers that may predict patient response, enhancing personalized medicine approaches in treatment. Overall, Pilaralisib represents a significant advancement in the development of targeted therapies within the realm of cancer treatment and immune modulation.

Formula: C₂₅H₂₅ClN₆O₄S

InChI: InChI=1/C21H16N6O2S2/c1-13-6-9-15(10-7-13)31(28,29)27-21-20(23-16-4-2-3-5-17(16)24-21)22-14-8-11-18-19(12-14)26-30-25-18/h2-12H,1H3,(H,22,23)(H,24,27)

InChI key: InChIKey=QINPEPAQOBZPOF-UHFFFAOYSA-N

SMILES: N(C=1C(NS(=O)(=O)C2=CC(NC(C(C)(C)N)=O)=CC=C2)=NC3=C(N1)C=CC=C3)C4=CC(OC)=CC=C4Cl

Synonyms:

• 2-Amino-N-[3-[N-[3-[(2-chloro-5-methoxyphenyl)amino]quinoxalin-2-yl]sulfamoyl]phenyl]-2-methylpropanamide
• 2-Amino-N-[3-[[3-(2-chloro-5-methoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-2-methylpropanamide
• 2-Amino-N-[3-[[[3-[(2-chloro-5-methoxyphenyl)amino]-2-quinoxalinyl]amino]sulfonyl]phenyl]-2-methylpropanamide
• 3-Cyano-5-fluorobenzaldehyde
• 3-Fluoro-5-formylbenzonitrile
• Benzonitrile, 3-fluoro-5-formyl-
• N-(3-(benzo[c][1,2,5]thiadiazol-5-ylamino)quinoxalin-2-yl)-4-methylbenzenesulfonamide
• N-[3-(2,1,3-Benzothiadiazol-5-ylamino)-2-quinoxalinyl]-4-methylbenzenesulfonamide
• Pilaralisib
• Propanamide, 2-amino-N-[3-[[[3-[(2-chloro-5-methoxyphenyl)amino]-2-quinoxalinyl]amino]sulfonyl]phenyl]-2-methyl-
• SC
• Sar 245408
• Sar245408
• Xl-147
• Xl147
• XL-147,Pilaralisib, SAR245408
• Pilaralisib (XL-147)
• XL-147; SAR245408;XL147;XL 147;SAR-245408;SAR 245408
• PILARALISIB (XL147);SAR245408;XL 147
• CS-1670
• XL-147;SAR245408;XL147;XL 147;SAR-245408;SAR 245408; PILARALISIB

Pilaralisib

CAS: 934526-89-3

Formula: C₂₅H₂₅ClN₆O₄S

Purity: 99%

Color and Shape: Solid

Molecular weight: 541.0218

Ref: IN-DA00GU7F

Pilaralisib

CAS: 934526-89-3

Pilaralisib

Purity: ≥98%

Molecular weight: 541.02g/mol

Ref: 54-BUP09837

Pilaralisib

CAS: 934526-89-3

Pilaralisib (XL-147) is an orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K).

Formula: C₂₅H₂₅ClN₆O₄S

Purity: 98.51% - 99.61%

Color and Shape: Solid

Molecular weight: 541.02

Ref: TM-T2365

Pilaralisib

Controlled Product

CAS: 934526-89-3

Applications Pilaralisib is a pan-PI3K inhibitor used in the treatment of patients with chronic lymphocytic leukemia or relapsed or refractory lymphoma.
References Brown, J. et alClin. Cancer Res., 21, 3160 (2015);

Formula: C₂₅H₂₅ClN₆O₄S

Color and Shape: Neat

Molecular weight: 541.02

Ref: TR-P441390

XL 147

CAS: 934526-89-3

Inhibits PI3K kinases

Formula: C₂₅H₂₅ClN₆O₄S

Purity: Min. 95%

Molecular weight: 541.02 g/mol

Ref: 3D-FX137599